Calcagno 2014.

Trial name or title	Not stated
Methods	Study design: parallel‐group trial Duration of follow‐up: 12 months Method of randomisation: not described Method of concealment of allocation: not described Blinding: not mentioned Power calculation: not mentioned Phases of the study: 2 (treatment phase, follow‐up phase)
Participants	Country of enrolment: not described Setting/location: not specified Diagnostic criteria (stable angina pectoris): not described Comorbidities: percutaneous coronary intervention plus stent implantation Inclusion criteria: not described Exclusion criteria: not described
Interventions	Number of intervention groups: 2 Concomitant medications: medical therapy (not described) Excluded medications: not mentioned No treatment group Intervention: none Duration of intervention: 30 days Ranolazine group Intervention: ranolazine (type of formulation not specified) (dose not reported) Duration of intervention: 30 days
Outcomes	Total number of outcomes: 5 (ETT parameters, symptoms, arrhythmia, angina during moderate exercises, re‐hospitalisation) OUTCOMES No outcome appears to meet the inclusion criteria
Starting date	Not reported
Contact information	Not provided
Notes